Literature DB >> 28912187

Pediatric Cardiomyopathies.

Teresa M Lee1, Daphne T Hsu2, Paul Kantor2, Jeffrey A Towbin2, Stephanie M Ware2, Steven D Colan2, Wendy K Chung2, John L Jefferies2, Joseph W Rossano2, Chesney D Castleberry2, Linda J Addonizio2, Ashwin K Lal2, Jacqueline M Lamour2, Erin M Miller2, Philip T Thrush2, Jason D Czachor2, Hiedy Razoky2, Ashley Hill2, Steven E Lipshultz2.   

Abstract

Pediatric cardiomyopathies are rare diseases with an annual incidence of 1.1 to 1.5 per 100 000. Dilated and hypertrophic cardiomyopathies are the most common; restrictive, noncompaction, and mixed cardiomyopathies occur infrequently; and arrhythmogenic right ventricular cardiomyopathy is rare. Pediatric cardiomyopathies can result from coronary artery abnormalities, tachyarrhythmias, exposure to infection or toxins, or secondary to other underlying disorders. Increasingly, the importance of genetic mutations in the pathogenesis of isolated or syndromic pediatric cardiomyopathies is becoming apparent. Pediatric cardiomyopathies often occur in the absence of comorbidities, such as atherosclerosis, hypertension, renal dysfunction, and diabetes mellitus; as a result, they offer insights into the primary pathogenesis of myocardial dysfunction. Large international registries have characterized the epidemiology, cause, and outcomes of pediatric cardiomyopathies. Although adult and pediatric cardiomyopathies have similar morphological and clinical manifestations, their outcomes differ significantly. Within 2 years of presentation, normalization of function occurs in 20% of children with dilated cardiomyopathy, and 40% die or undergo transplantation. Infants with hypertrophic cardiomyopathy have a 2-year mortality of 30%, whereas death is rare in older children. Sudden death is rare. Molecular evidence indicates that gene expression differs between adult and pediatric cardiomyopathies, suggesting that treatment response may differ as well. Clinical trials to support evidence-based treatments and the development of disease-specific therapies for pediatric cardiomyopathies are in their infancy. This compendium summarizes current knowledge of the genetic and molecular origins, clinical course, and outcomes of the most common phenotypic presentations of pediatric cardiomyopathies and highlights key areas where additional research is required. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifiers: NCT02549664 and NCT01912534.
© 2017 American Heart Association, Inc.

Entities:  

Keywords:  epidemiology; genetics; pediatrics

Mesh:

Substances:

Year:  2017        PMID: 28912187      PMCID: PMC5657298          DOI: 10.1161/CIRCRESAHA.116.309386

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  172 in total

1.  Circulating microRNA as a biomarker for recovery in pediatric dilated cardiomyopathy.

Authors:  Shelley D Miyamoto; Anis Karimpour-Fard; Valencia Peterson; Scott R Auerbach; Kurt R Stenmark; Brian L Stauffer; Carmen C Sucharov
Journal:  J Heart Lung Transplant       Date:  2015-01-30       Impact factor: 10.247

2.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

3.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

4.  The Burden of Early Phenotypes and the Influence of Wall Thickness in Hypertrophic Cardiomyopathy Mutation Carriers: Findings From the HCMNet Study.

Authors:  Carolyn Y Ho; Sharlene M Day; Steven D Colan; Mark W Russell; Jeffrey A Towbin; Mark V Sherrid; Charles E Canter; John L Jefferies; Anne M Murphy; Allison L Cirino; Theodore P Abraham; Matthew Taylor; Luisa Mestroni; David A Bluemke; Petr Jarolim; Ling Shi; Lynn A Sleeper; Christine E Seidman; E John Orav
Journal:  JAMA Cardiol       Date:  2017-04-01       Impact factor: 14.676

5.  In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy.

Authors:  Christopher E Nelson; Chady H Hakim; David G Ousterout; Pratiksha I Thakore; Eirik A Moreb; Ruth M Castellanos Rivera; Sarina Madhavan; Xiufang Pan; F Ann Ran; Winston X Yan; Aravind Asokan; Feng Zhang; Dongsheng Duan; Charles A Gersbach
Journal:  Science       Date:  2015-12-31       Impact factor: 47.728

6.  Sudden death in childhood cardiomyopathy: results from a long-term national population-based study.

Authors:  Tara Bharucha; Katherine J Lee; Piers E F Daubeney; Alan W Nugent; Christian Turner; Gary F Sholler; Terry Robertson; Robert Justo; Jim Ramsay; John B Carlin; Steven D Colan; Ingrid King; Robert G Weintraub; Andrew M Davis
Journal:  J Am Coll Cardiol       Date:  2015-06-02       Impact factor: 24.094

7.  Prevalence, morbidity, and mortality of heart failure-related hospitalizations in children in the United States: a population-based study.

Authors:  Joseph W Rossano; Jeffrey J Kim; Jamie A Decker; Jack F Price; Farhan Zafar; Daniel E Graves; David L S Morales; Jeffrey S Heinle; Biykem Bozkurt; Jeffrey A Towbin; Susan W Denfield; William J Dreyer; John L Jefferies
Journal:  J Card Fail       Date:  2012-04-10       Impact factor: 5.712

8.  Renin-angiotensin system gene polymorphisms as potential modifiers of hypertrophic and dilated cardiomyopathy phenotypes.

Authors:  Bindu Rani; Amit Kumar; Ajay Bahl; Rajni Sharma; Rishikesh Prasad; Madhu Khullar
Journal:  Mol Cell Biochem       Date:  2017-01-24       Impact factor: 3.396

9.  Usefulness of Serial N-terminal Pro-B-type Natriuretic Peptide Measurements to Predict Cardiac Death in Acute and Chronic Dilated Cardiomyopathy in Children.

Authors:  Susanna L den Boer; Dimitris Rizopoulos; Gideon J du Marchie Sarvaas; Ad P C M Backx; Arend D J Ten Harkel; Gabriëlle G van Iperen; Lukas A J Rammeloo; Ronald B Tanke; Eric Boersma; Willem A Helbing; Michiel Dalinghaus
Journal:  Am J Cardiol       Date:  2016-08-30       Impact factor: 2.778

10.  Prospective Evaluation of Sleep Apnea as Manifestation of Heart Failure in Children.

Authors:  Susanna L den Boer; Koen F M Joosten; Sandra van den Berg; Ad P C M Backx; Ronald B Tanke; Gideon J du Marchie Sarvaas; Willem A Helbing; Lukas A J Rammeloo; Arend D J ten Harkel; Gabriëlle G van Iperen; Michiel Dalinghaus
Journal:  Pediatr Cardiol       Date:  2015-10-16       Impact factor: 1.655

View more
  56 in total

Review 1.  Genetic Basis for Congenital Heart Disease: Revisited: A Scientific Statement From the American Heart Association.

Authors:  Mary Ella Pierpont; Martina Brueckner; Wendy K Chung; Vidu Garg; Ronald V Lacro; Amy L McGuire; Seema Mital; James R Priest; William T Pu; Amy Roberts; Stephanie M Ware; Bruce D Gelb; Mark W Russell
Journal:  Circulation       Date:  2018-11-20       Impact factor: 29.690

Review 2.  Cardiac transplantation in children.

Authors:  C S Black; A Khushnood; H Holtby; L Hepburn
Journal:  BJA Educ       Date:  2019-02-10

Review 3.  Pediatric heart transplantation: long-term outcomes.

Authors:  Anne I Dipchand; Jessica A Laks
Journal:  Indian J Thorac Cardiovasc Surg       Date:  2019-05-29

Review 4.  Genetics of inherited cardiomyopathies in Africa.

Authors:  Gasnat Shaboodien; Timothy F Spracklen; Stephen Kamuli; Polycarp Ndibangwi; Carla Van Niekerk; Ntobeko A B Ntusi
Journal:  Cardiovasc Diagn Ther       Date:  2020-04

Review 5.  Left Ventricular Noncompaction Detected by Cardiac Magnetic Resonance Screening: A Reexamination of Diagnostic Criteria.

Authors:  Anthony H Masso; Carlo Uribe; James T Willerson; Benjamin Y Cheong; Barry R Davis
Journal:  Tex Heart Inst J       Date:  2020-06-01

Review 6.  Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Authors:  Antoine Bondue; Eloisa Arbustini; Anna Bianco; Michele Ciccarelli; Dana Dawson; Matteo De Rosa; Nazha Hamdani; Denise Hilfiker-Kleiner; Benjamin Meder; Adelino F Leite-Moreira; Thomas Thum; Carlo G Tocchetti; Gilda Varricchi; Jolanda Van der Velden; Roddy Walsh; Stephane Heymans
Journal:  Cardiovasc Res       Date:  2018-08-01       Impact factor: 10.787

7.  Dilated cardiomyopathy with endocardial fibroelastosis in a juvenile Pallas cat.

Authors:  Erwin K Gudenschwager; Jonathan A Abbott; Tanya LeRoith
Journal:  J Vet Diagn Invest       Date:  2019-01-29       Impact factor: 1.279

8.  Functional limitations and educational needs among children and adolescents with heart disease.

Authors:  Sherry L Farr; Karrie F Downing; Tiffany Riehle-Colarusso; Ginnie Abarbanell
Journal:  Congenit Heart Dis       Date:  2018-07-22       Impact factor: 2.007

9.  Potential Common Pathogenic Pathways for the Left Ventricular Noncompaction Cardiomyopathy (LVNC).

Authors:  Ying Liu; Hanying Chen; Weinian Shou
Journal:  Pediatr Cardiol       Date:  2018-05-15       Impact factor: 1.655

10.  Epidemiology of Pediatric Hypertrophic Cardiomyopathy in a 10-Year Medicaid Cohort.

Authors:  Deipanjan Nandi; Emily A Hayes; Yinding Wang; Jeanette M Jerrell
Journal:  Pediatr Cardiol       Date:  2020-10-03       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.